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BACKGROUND AND PURPOSE
The aim of the study was to determine whether KCNQ channels are functionally expressed in bladder smooth muscle cells
(SMC) and to investigate their physiological significance in bladder contractility.
EXPERIMENTAL APPROACH
KCNQ channels were examined at the genetic, protein, cellular and tissue level in guinea pig bladder smooth muscle using
RT-PCR, immunofluorescence, patch-clamp electrophysiology, calcium imaging, detrusor strip myography, and a panel of
KCNQ activators and inhibitors.
KEY RESULTS
KCNQ subtypes 1–5 are expressed in bladder detrusor smooth muscle. Detrusor strips typically displayed TTX-insensitive
myogenic spontaneous contractions that were increased in amplitude by the KCNQ channel inhibitors XE991, linopirdine or
chromanol 293B. Contractility was inhibited by the KCNQ channel activators flupirtine or meclofenamic acid (MFA). The
frequency of Ca2+-oscillations in SMC contained within bladder tissue sheets was increased by XE991. Outward currents in
dispersed bladder SMC, recorded under conditions where BK and KATP currents were minimal, were significantly reduced by
XE991, linopirdine, or chromanol, and enhanced by flupirtine or MFA. XE991 depolarized the cell membrane and could evoke
transient depolarizations in quiescent cells. Flupirtine (20 μM) hyperpolarized the cell membrane with a simultaneous
cessation of any spontaneous electrical activity.
CONCLUSIONS AND IMPLICATIONS
These novel findings reveal the role of KCNQ currents in the regulation of the resting membrane potential of detrusor SMC
and their important physiological function in the control of spontaneous contractility in the guinea pig bladder.
Abbreviations
BK, large conductance calcium activated potassium channel; IC, interstitial cell; IK, intermediate conductance calcium
activated potassium channel; K2P, two-pore domain potassium channels; KATP, ATP-sensitive potassium channel; Kv,
voltage-gated potassium channels; MFA, meclofenamic acid; SK, small conductance calcium activated potassium
channel; SMC, smooth muscle cell; TTX, tetrodotoxin
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Introduction
The ability of the bladder to store and expel urine is achieved
through the interaction of the complex arrangement of cells
that make up the bladder wall, which include the urothelium,
nerves, smooth muscle cells (SMC) and populations of inter-
stitial cells (ICs). Spontaneous contractile activity is a phe-
nomenon common to many smooth muscle preparations
and, in the urinary bladder, is considered to underlie the
basal tone which enables the bladder to maintain an
optimum shape as it expands to accommodate increasing
volumes of urine (Turner and Brading, 1997).
Potassium channels have an important role in controlling
bladder contractility by regulating the resting membrane
potential (r.m.p.) of its SMC and repolarizing the action
potential (Petkov, 2011). Several types of potassium currents
have been characterized in bladder SMC, including those
carried by large-conductance calcium-activated potassium
channels (BK) (Imaizumi et al., 1998; Petkov et al., 2001a;
Herrera and Nelson, 2002), intermediate-conductance
calcium-activated potassium channels (IK) (Ohya et al.,
2000), small conductance calcium-activated potassium chan-
nels (SK) (Herrera and Nelson, 2002), voltage-gated potassium
channels (Kv) (Thorneloe and Nelson, 2003), ATP-sensitive
potassium channels (KATP) (Bonev and Nelson, 1993; Petkov
et al., 2001b) and two-pore domain K channels (K2P; channel
nomenclature follows Alexander et al., 2011). In bladder
smooth muscle, BK channels control action potential dura-
tion and the r.m.p., whereas SK currents underlie after-
hyperpolarizations (Herrera and Nelson, 2002). Kv currents
contribute to the regulation of the r.m.p. in addition to repo-
larizing the action potential (Thorneloe and Nelson, 2003).
While there is little convincing evidence that KATP channels
are active under normal physiological conditions, activation
of these channels generates membrane hyperpolarization,
reduction in action potential firing and subsequent bladder
relaxation (Petkov, 2011). Recent work on K2P channels shows
their involvement in r.m.p. maintenance and sensing or
responding to environmental factors, such as pH (Beckett
et al., 2008) or stretch (Baker et al., 2008).
KCNQ (Kv7) currents are outwardly rectifying, voltage
dependent K+ currents that activate at potentials positive to
−60 mV and show little inactivation (Robbins, 2001). KCNQ
channels belong to the Kv family, comprise six transmem-
brane domains and a pore forming loop (6TMD-1P), and have
been widely studied in the nervous system, heart and inner
ear (Jentsch, 2000; Robbins, 2001). Five genes encoding the
KCNQ family of ion channel proteins have been identified,
each encoding a different KCNQ α-subunit (1–5). KCNQ1 was
initially identified in cardiomyocytes (Wang et al., 1996) and
was found to underlie the slow delayed rectifier current (IKs)
(Sanguinetti et al., 1996; Romey et al., 1997). Channelopa-
thies result in late repolarization and prolongation of the
cardiac action potential, as occurs in long QT syndrome,
associated with cardiac arrhythmias and sudden death (Wang
et al., 1996; Seebohm et al., 2003). KCNQ2, 3 and 5 generate
M-type currents in the nervous system (Wang et al., 1998;
Selyanko et al., 2001; Shah et al., 2002; Delmas and Brown,
2005) and KCNQ2 and KCNQ3 gene mutations contribute to
benign familial neonatal convulsions or epilepsy (Biervert
et al., 1998; Schroeder et al., 1998). In addition to brain and
nervous tissue, KCNQ5 is also expressed in skeletal muscle
(Schroeder et al., 2000). Genetic mutations of KCNQ4 in hair
cells of the cochlea (Rennie et al., 2001; Liang et al., 2006)
lead to a form of autosomal dominant progressive deafness
(Kubisch et al., 1999). KCNQ4 is also expressed in heart, brain
and skeletal muscle (Kharkovets et al., 2000), and shares char-
acteristics of M current (Søgaard et al., 2001).
In vascular smooth muscle, KCNQ channel modulators
have been used to demonstrate that KCNQ currents are
present in murine portal vein (Ohya et al., 2003; Yeung and
Greenwood, 2005; Yeung et al., 2007), rat pulmonary artery
(Joshi et al., 2006), rat stomach (Ohya et al., 2002) and rat
mesenteric artery (Mackie et al., 2008) in addition to myome-
trial smooth muscle (McCallum et al., 2009). KCNQ currents
are important in the regulation of vascular smooth muscle
contractility and vascular tone. Emerging evidence indicates
that KCNQ channels might also be present in the bladder as
Streng et al. (2004) demonstrated that the KCNQ activator,
retigabine, decreased capsaicin-induced bladder overactivity
or hypercontractility when delivered intravesically to con-
scious rats. Furthermore, Rode et al. (2010) demonstrated
effects on rat bladder contractility by KCNQ drugs. Gene
expression of KCNQ1, 4 and 5 and protein expression of
KCNQ4 by Western blotting was recently reported for rat
bladder (Svalø et al., 2011). Our previous report of KCNQ
currents in ICs of the guinea pig detrusor, which contributed
to the r.m.p. (Anderson et al., 2009), showed that KCNQ
channels were functional in the bladder.
The aims of the present study were to investigate whether
KCNQ currents comprised a component of the total outward
current in bladder SMC; to examine whether KCNQ drugs
altered the r.m.p. of bladder SMC; and to determine whether
KCNQ modulators could affect spontaneous contractile activ-
ity or Ca2+-oscillations in bladder tissues. Gene and protein
expression of KCNQ channels was investigated using molecu-
lar and immunohistochemical techniques. Some preliminary
findings of this study have been presented to the Physiologi-
cal Society (Carson and McCloskey, 2007).
Methods
Ethical approval
All animal care and experimental protocols were in accord-
ance with Schedule 1, Animal Scientific Procedures Act, 1986,
UK, and approved by the local ethics committee, Queen’s
University Belfast. Bladders were removed from male Dunkin-
Hartley guinea pigs (Harlan, UK) (200–500 g) that had been
killed humanely by cervical dislocation. All studies involving
animals are reported in accordance with the ARRIVE guide-
lines for reporting experiments involving animals (Kilkenny
et al., 2010; McGrath et al., 2010). A total of 121 animals were
used in the experiments described here.
Cell preparation
Bladders were opened by longitudinal incision and the
mucosa removed to leave the underlying detrusor. Cells were
enzymically isolated from the detrusor region as previously
described (McCloskey and Gurney, 2002). A heterogeneous
yield of cells was typically obtained, including non-
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contractile IC, which were identified by their branched
morphology, and a larger population of typical elong-
ated spindle-shaped SMC which contracted readily upon
depolarization. The latter cells were selected for patch clamp
experiments.
Electrophysiological recordings
Immediately after dispersal, cells were plated at the bottom of
a recording chamber for amphotericin perforated patch-
clamp experiments. The bath was constantly perfused with
Hanks-PSS (see below for composition) solution at room tem-
perature and the cell of interest was continuously superfused
by a drug delivery system consisting of a pipette tip with
diameter of 200 μm placed approximately 300 μm away.
Borosilicate microelectrodes (2–4 MΩ) were connected via
an AD/DA converter (National Instruments Inc., Berkshire,
UK) to an Axopatch-1D amplifier (Axon Instruments;
Molecular Devices, Sunnyvale, CA, USA) and a personal com-
puter running WinWCP software (Dr Dempster, University of
Strathclyde). After gigaseals were obtained, the cell was given
a test depolarization (from −60 mV to 40 mV) every 30 s until
the outward current developed to its maximal amplitude.
Series resistance and the capacitive surge were compensated
using circuitry from the Axopatch-1D amplifier. Bladder SMC
had mean cell capacitance of 51.5 ± 1.5pF, n = 82. In voltage-
clamp experiments, current amplitude (pA) was divided by
the cell capacitance (pF) to give current density, pA/pF.
RNA extraction and reverse transcription-PCR
Total RNA was extracted from freshly dispersed detrusor cells.
Cells were repeatedly washed in PSS by centrifuging, removal
of the supernatant, replacing with fresh PSS to minimize the
presence of cell debris and to improve the purity of the
detrusor cell sample. Guinea pig heart and brain tissue were
used as positive controls. The tissue was cut into 5 mg pieces
and placed in 150 μL lysis buffer, which also contained
4 ng·μL−1 carrier RNA (Qiagen, Manchester, UK). Tissue was
immediately homogenized using a conventional rotor-stator
homogenizer for 20–40 s. Proteinase K solution was then
added to the homogenate (RNeasy Kit, Qiagen) and incubated
at 55°C for 10 min before being centrifuged (2 min, maximum
speed) through a QIAshredder (Qiagen). RNA extraction from
freshly dispersed bladder cells followed a similar protocol with
the exception of homogenization. Total RNA was extracted
using RNeasy mini Elute spin columns (Qiagen), which
included on-column DNase I treatment. RNA content was
quantified using a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA). The super-
script III RT (Invitrogen, Paisley, UK) and a mixture of
oligo(dt) primer and random hexamers were used to reverse
transcribe the RNA samples. In negative controls, addition of
reverse transcriptase was omitted. cDNA was then added to a
Hot start Taq polymerase master mix (Qiagen) to which
guinea pig KCNQ 1–5 forward and reverse primers (Table 1)
were incorporated. KCNQ 1, 2, 3 and 5 primers for RT-PCR
used sequences that were demonstrated to work reliably on
guinea pig and rat cochlea KCNQ subtypes (Liang et al., 2006),
whereas KCNQ 4 primers were designed online using Primer
3: all were purchased from MWG-Biotech. The thermal cycler
program used for PCR amplification included a 1 min 95°C
denaturation step, a 30 s annealing step, using individual
optimized annealing temperatures specific for each primer
pair, followed by a 30 s primer extension step at 68°C for 38
cycles. PCR products were separated on 1% agarose (Melford,
Ipswich, UK) gels in Tris-borate-EDTA (TBE) buffer (Fisher
Scientific, Loughborough, UK), visualized with ethidium
bromide staining and documented using a UVIdoc gel system.
PCR products were confirmed by sequencing in the University
of Manchester Core Facility.
Immunohistochemistry
Detrusor preparations were fixed in 4% paraformaldehyde,
washed in PBS, blocked in 1% BSA and incubated with
primary antibodies (in 0.05% Triton-X 100) to KCNQ sub-
types 1–5 (KCNQ1 (APC-022), KCNQ2 (APC-050) KCNQ3
(APC-051) from Alomone, 1:200; KCNQ 4 (sc-50417) and
KCNQ5 (sc-50416) from Santa Cruz (1:200)) for 24 h. After
washing in PBS to remove excess antibody, tissues were incu-
bated in secondary fluorescent antibodies (Alexa 488 anti-
rabbit, 1:200, Invitrogen) for 1 h. Immunolabelled tissues
were imaged with confocal microscopy (Nikon C1) mounted
on a Nikon e90i upright microscope equipped with a 488 nm
argon ion laser and the resulting emission fluorescence
Table 1
Guinea pig oligonucleotide sequence of primers used for RT-PCR
Subtypes Primer sequence (forward and reverse) Product length (bp)
KCNQ1 Forward – 5′ GCT CTG GCC ACC GGG ACC CT-3′
Reverse – 5′ GAT GCG GCC GGA CTC ATT CA-3′
434
KCNQ2 Forward – 5′ CAA GTA CCC TCA GAC CTG GAA–3′
Reverse – 5′ CAG CTC TTG GGC ACC TTG CT–3′
515
KCNQ3 Forward – 5′ CCA AGG AAT GAA CCA TAT GTA GCC-3′
Reverse – 5′ CAG AAG AGT CAA GAT GGG CAG GAC-3′
461
KCNQ4 Forward – 5′ CGC TTC CGG GCC TCT CTA AGA C-3′
Reverse – 5′ GTC CTC GTG GTC TAC AGG GCT GTG-3′
561
KCNQ5 Forward – 5′ CCA TTG TTC TCA TCG CTT CA-3′
Reverse – 5′ TCC AAT GTA CCA GGC TGT GA–3′
200
BJP U A Anderson et al.
1292 British Journal of Pharmacology (2013) 169 1290–1304
collected through appropriate filters to a photomultiplier
tube. Control experiments were carried out as following: (i)
omission of the primary antibody to control for the specific-
ity of the secondary antibody; (ii) no antibodies to control for
autofluorescence of the tissue; (iii) absorption of the primary
antibody with control antigen (where available) to control for
the specificity of the primary antibody. Significant fluores-
cence was not observed in any of the control samples.
Organ bath contractile studies
After mucosa removal, strips of detrusor (10 mm × 2 mm ×
2 mm) were mounted in organ baths to an initial tension of
1 g. Tension was readjusted to 1 g after the strips initially
relaxed (1–2 times) until spontaneous contractile activity
occurred. This activity was maintained for at least 4 h in the
absence of drugs or in the presence of drug vehicles (Figure 2F).
Tissues were perfused (1–2 mL per minute) with Krebs solution
(see below for composition), 37°C, pH 7.4) and equilibrated
for 1 h. Experiments were performed using Intracept Chart
Software. The following parameters were measured: phasic
contraction amplitude; phasic contraction frequency; area
under the phasic contraction curve and tone. Measurements
were made over a period of 10 min before and 3 min during
exposure to a drug once the maximal effect was achieved. Data
were normalized and expressed as % of control.
Fluorescent calcium imaging
Preparations of guinea pig bladder containing several smooth
muscle bundles were pinned to the Sylgard base of a record-
ing chamber and loaded with Fluo-4 AM (Invitrogen; 1–5 μM
in 0.03% Pluronic) for 30 min. Recordings commenced after
preparations were perfused (2 mL·min−1) with HEPES-Krebs
solution (see below for composition) at 35°C for at least
20 min. Tissues were imaged with a Nikon 80i upright epif-
luorescent imaging system equipped with an EMCCD camera
(DQC-FS, Nikon UK Ltd., Kingston-upon-Thames, UK) via a
water dipping objective lens. Data was recorded using Win-
Fluor software (v3.2.25, Dr Dempster, University of Strath-
clyde) at a frame rate of 20–30 frames per second using 2 × 2
binning from WinFluor, which represented an acceptable
compromise between acquisition speed and image resolution.
Offline analysis of Ca2+-oscillations involved drawing a
region of interest (ROI) on the SMC and a ROI on part of the
image where there were no active cells so that background
fluorescence could be subtracted from all measurements. The
background-corrected fluorescence (F) at any time point was
normalized to baseline fluorescence (F0). F0 was calculated as
average fluorescence during 100 frames when there was no
activity. The frequency of events was measured in WinFluor
and analyzed in Microsoft Excel and Prism software (v4.02,
Graphpad, La Jolla, CA, USA).
Data analysis
Results from electrophysiological experiments are summa-
rised as means ± SEM. Statistical comparisons were made
using the Student’s paired t-test or ANOVA (where more than
one intervention occurred) with P < 0.05 considered as sig-
nificant. Data from the organ bath experiments are summa-
rised as means ± SEM and analysed with Student’s t-test,
where P < 0.05 was considered as significant. The number of
tissues is referred to as ‘n’; experimental series contained
tissues from at least four animals. Data from the Ca2+ imaging
are expressed as mean ± SEM, and statistical comparisons
were made with ANOVA or Student’s paired t-test with P < 0.05
considered as significant. The number of observations in an
experimental group is denoted as ‘n’. Data were analyzed
with Origin (Origin Lab, Northampton, MA, USA), Microsoft
Excel and Prism (Graphpad) software.
Materials
Solutions used were of the following compositions (mM):
(1) Hanks’ Ca2+-free solution: 141 Na+, 5.8 K+, 130.3 Cl−, 15.5
HCO3−, 0.34 HPO42−, 0.44 H2PO4−, 10 HEPES, 10 glucose
and 2.9 sucrose, pH 7.40.
(2) Hanks solution (PSS): 130 Na+, 5.8 K+, 135 Cl−, 4.16
HCO3−, 0.44 H2PO4−, 0.34 HPO42−, 0.4 SO42−, 1.8 Ca2+,
0.9Mg2+, 10 HEPES, 10 glucose and 2.9 sucrose, pH 7.40.
(3) Modified pipette solution to eliminate contribution from
Ca2+-activated K+ and KATP: 130 K+, 6.2 Na+, 110 gluconate,
21 Cl−, 0.5 Mg2+, 3 ATP (Na+ salt), 0.1 GTP, 5 HEPES, 5
EGTA, pH 7.2;
(4) Cs+ pipette solution: 130 Cs+, 10.2 Na+, 131 Cl−, 0.5 Mg2+,
2.5 ATP (Na+ salt), 0.1 GTP, 2.5 phosphocreatine, 5 HEPES,
1 EGTA, pH 7.2.
(5) Krebs solution for organ bath tension recordings:
146.2 Na+, 5.9 K+, 133.3 Cl, 25 HCO3−, 1.2 H2PO4−, 11
glucose, 2.5 Ca2+, 1.2 Mg2+ constantly gassed with 95%
O2/5% CO2.
(6) HEPES-Krebs for calcium imaging: 125 NaCl, 5.36 KCl, 11
glucose, 10 HEPES, 0.44 KH2PO4, 0.33 NaH2PO4, 1 MgCl2,
1.8 CaCl2.
Stock solutions of XE991, linopirdine (Tocris, Abingdon,
UK), meclofenamic acid (Sigma, UK) were made in distilled
water; chromanol 293B and flupirtine (Sigma) were dissolved
in DMSO. The final concentration of DMSO was 0.1% which
does not affect spontaneous activity in this preparation
(Hashitani and Brading, 2003).
Results
Functional effect of compounds acting on
KCNQ channels in guinea pig bladder strips
During equilibration, detrusor strips typically developed
myogenic spontaneous contractions that were maintained
for several hours. Experiments were carried out in the pres-
ence of 1 μM tetrodotoxin to eliminate any effect of the
compounds tested on neuronal channels. Application of
the KCNQ channel inhibitor XE991 (10 μM) (Wang et al.,
1998; Zaczek et al., 1998) enhanced contractility (Figure 1A).
XE991 significantly increased AUC and amplitude (P < 0.05,
n = 13), but did not significantly affect frequency (P > 0.05,
Figure 1D–F) or baseline tone (P > 0.05). Two other KCNQ
channel inhibitors, linopirdine and chromanol 293B, also
enhanced spontaneous activity (Figure 1B, C), significantly
increasing amplitude and AUC (P < 0.05, n = 5 and n = 9
respectively, Figure 1D,F) but neither drug affected frequency
(P > 0.05, Figure 1E) nor baseline tone (P > 0.05).
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The anti-convulsant and muscle relaxant flupirtine
(Friedel and Fitton, 1993; Kapetanovic et al., 1995), activates
KCNQ currents, reducing excitability in neurons (Wladyka
and Kunze, 2006). Yeung et al. (2007), demonstrated
flupirtine-induced relaxation of pre-contracted blood vessels,
similar to the structurally related drug, retigabine (Main et al.,
2000; Tatulian et al., 2001; Wuttke et al., 2005). Flupirtine
reduced spontaneous contraction amplitude in bladder strips
(P < 0.05, n = 6, Figure 2), with little effect on frequency, but
reduced baseline tone (n = 6, P < 0.05). Another KCNQ 2/3
activator meclofenamic acid (MFA) was tested (Peretz et al.,
2005) and found to significantly reduce contraction ampli-
tude, AUC and baseline tone (n = 5, P < 0.05; Figure 2B–E),
without affecting frequency (P > 0.05). A time-dependent
control demonstrating maintenance of spontaneous activity
under these experimental conditions, in the absence of drugs,
is shown in Figure 2F.
Effects of XE991 on calcium oscillations in
SMC within tissue sheets
Fluo-4AM loaded bladder tissue preparations containing
several smooth muscle bundles, exhibited Ca2+-oscillations
and smaller localized events in individual SMC, in addition to
coordinated whole bundle flashes (Figure 3). Flashes typically
originated at one or both edges of the smooth muscle bundle
and propagated to the opposite side. Post hoc x-t analysis of
A
XE991 (10 µM)
linopirdine (50 µM)
chromanol (30 µM)
2 mN
2 min
2 mN
2 mN
2 min
2 min
B
C
D
A
U
C
(%
 c
o
n
tr
o
l)
F
re
q
u
en
cy
(%
 c
o
n
tr
o
l)
A
m
p
lit
u
d
e
(%
 c
o
n
tr
o
l)
250 150
300
200
100
0
100
50
0
200
150
100
n = 13 n = 5 n = 9
50
0
XE991 Lino Chr
n = 13 n = 5 n = 9
XE991 Lino Chr
n = 13 n = 5 n = 9
XE991 Lino Chr
E F
Figure 1
KCNQ channel inhibitors enhance spontaneous contractile activity of bladder strips. (A) An example of the effect of XE991 (10 μM) on myogenic
spontaneous activity in a detrusor strip. (B) Linopirdine (Lino; 50 μM) also augmented the amplitude of spontaneous contractions. (C) Example
of the increase in contraction amplitude by chromanol 293B (Chr; 30 μM). (D) Summary bar chart of the effect of KCNQ inhibitors on contractility
measured as area under curve (AUC) and expressed relative to control (100%). (E) Summary bar chart of the effect of KCNQ inhibitors on
frequency. (F) Summary of the effect of KCNQ inhibitors on contraction amplitude. All experiments were carried out in the presence of
tetrodotoxin (1 μM). *P < 0.05, significantly different from control.
BJP U A Anderson et al.
1294 British Journal of Pharmacology (2013) 169 1290–1304
fluorescence intensity demonstrated travel of flashes across
the width of the bundle (Figure 3A,C). Application of XE991
(10 μM) significantly enhanced the frequency of whole
bundle Ca2+ flashes (Figure 3D, n = 5, P < 0.05). Analysis
of Ca2+-oscillations in individual SMC within the bundle
showed that large Ca2+-transients occurred along the length
of the cell in addition to smaller, localized Ca2+ events
(Figure 3B), both of which were increased by XE991.
Effects of XE991 on SMC outward currents
and the r.m.p.
Bladder SMC were voltage clamped using K+-filled pipettes
containing 5 mM EGTA and 3 mM ATP to inhibit Ca2+-
activated K+ and KATP channels and depolarized to evoke
outward potassium currents. This approach was successfully
used by Evans et al. (1996) and Yeung and Greenwood (2005),
and avoids the use of channel blocking drugs, which may
interfere with the conductance of interest. Typical outward
currents evoked on stepping to +40 mV from a holding poten-
tial of −60 mV, followed by repolarization to −60 mV are
shown in Figure 4A. To test the idea that a component of the
outward current was mediated by KCNQ channels, XE991 (3,
10 and 30 μM) was applied to the cell. XE991 reduced the
control current in a concentration-dependent manner with
mean current reduced from 620pA ± 104pA to 507 ± 94pA by
10 μM XE991 (n = 7, P < 0.01), and further reduced to 402pA
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Figure 2
KCNQ channel openers reduce contractility of bladder strips. (A) Example of the reduction in contraction amplitude by the KCNQ opener,
flupirtine (20 μM). (B) Meclofenamic acid (MFA; 1 μM) also reduced contraction amplitude. (C, D, E) Summary bar charts for the effects of
flupirtine and MFA on contractility measured as area under curve (AUC), frequency and contraction amplitude respectively. All experiments were
carried out in the presence of tetrodotoxin (1 μM). *P < 0.05, significantly different from control. (F) Trace from a time-dependent control showing
maintenance of spontaneous activity over several hours.
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± 34pA by 30 μM XE991 (P < 0.01). The XE991-sensitive
current was obtained by subtracting the trace in 30 μM XE991
from the control trace (inset) showing the typical non-
inactivating nature of the current. Current amplitude evoked
at +40 mV in the presence of drug was normalized to control
and mean current (± SEM) was plotted as % inhibition against
concentration in Figure 4B. Data was fitted with a Hill equa-
tion (E/Emax = Emin + (Emax − Emin)[xn/(kn + xn)] where E/Emax was
the relative response to XE991, kn was the IC50 and n was the
Hill coefficient). The XE991 IC50 was 9.9 ± 0.003 μM.
XE991 (10 μM) reduced the amplitude of currents across
the voltage range tested in Figure 4C. The current–voltage
relationship of mean current density in the absence and
presence of drug (n = 8) is shown in Figure 4D, with the inset
showing current density at potentials between −50 and
−20 mV. Although inhibition of outward current by XE991
occurred within 3 min, previous studies have shown variable
time courses for maximal effect (Gu et al., 2005; Yeung and
Greenwood, 2005; Joshi et al., 2006; Vervaeke et al., 2006). In
the present study, XE991 was applied for up to 10 min, and
its reduction of outward current was not reversed on
washout.
As KCNQ currents have different sensitivities to tetraethy-
lammonium (TEA) depending on their composition of spe-
Figure 3
The effect of XE991 on calcium oscillations in SMC within tissue sheets. (A) Bladder tissue preparation loaded with the calcium indicator Fluo-4AM
showing 2 smooth muscle bundles (SM). Activity was analysed with a region of interest (ROI) and a line drawn across the bundle. (i) Intensity–time
plot of activity in the ROI showing XE991-induced (10 μM) enhancement in the frequency of whole bundle calcium flashes. (ii) Post hoc x-t analysis
of fluorescence intensity demonstrates occurrence of the flashes across the width of the bundle. (B) (i) ROI analysis of the smooth muscle cell at
the edge of the bundle as indicated on the micrograph showing that activity within a single smooth muscle cell is augmented by XE991. Large
Ca2+-transients (arrow) occurred along the length of the cell, as shown in the line analysis below (ii). Smaller, localized Ca2+ events did not
propagate along the cell length (arrowhead). Both types of Ca2+ signals were increased by XE991. (C) Consecutive frames from the whole bundle
flash highlighted in A show the spread of Ca2+ signal across the bundle from right to left. (D) Summary bar chart of the significant increase in the
frequency of smooth muscle bundle flashes by XE991. Control bar refers to pre-drug spontaneous activity. *P < 0.05, significantly different from
control: n = 5.
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cific KCNQ α-subunits (see Discussion), XE991 was tested in
the presence of TEA. After TEA exposure (30 mM), XE991
(30 μM) significantly reduced the residual outward current
from 60pA ± 10pA to 47pA ± 10pA (n = 5, P < 0.05). As the
electrode solution contained 5 mM EGTA, any blocking effect
of TEA would be expected to be on Kv and not BK, indicating
that KCNQ subtypes were present, some of which were
TEA-insensitive.
The action of KCNQ modulators in the contractile experi-
ments could be explained by an effect on bladder SMC r.m.p.
Bladder SMC studied in current clamp-mode had mean r.m.p.
of −32 mV ± 2 (n = 14, range from −23 mV to −45 mV), and
although the majority of cells were quiescent, spontaneous
oscillations were sometimes observed (5/14 cells). XE991
(10 μM) produced membrane depolarization (mean 20 ±
3 mV; n = 6, P < 0.05, Figure 4E) that was maintained during
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Figure 4
Effect of XE991 on outward current and resting membrane potential in SMC. (A) Currents were evoked by stepping from −60 mV to +40 mV using
a pipette solution containing EGTA (5 mM) and ATP (3 mM) to eliminate BK and KATP currents. XE991 reduced the total outward current in a
concentration-dependent fashion. The inset trace shows the non-inactivating XE991-sensitive current, obtained by subtracting the trace in 30 μM
XE991 from the control trace. (B) Concentration–response curve for the effect of XE991 on peak outward current. Current amplitude in presence
of drug was normalized to control and plotted as % inhibition. Mean data for seven cells was fitted with a Hill equation, which calculated the IC50
to be 9.9 ± 0.003 μM. (C) Family of currents evoked by stepping from −60 mV to a range of increasingly positive potentials as denoted in the
voltage protocol. XE991 (10 μM) reduced the amplitude of outward currents across the voltage range. (D) Summary current density–voltage
graph illustrating the effect of XE991 in eight cells. Inset shows the current density data for −50 mV to −20 mV on an expanded scale. *P < 0.05,
significant effect of XE991. (E) An example of the depolarization caused by XE991 (10 μM) in a quiescent SMC (upper trace). The XE991-evoked
depolarization was sometimes sufficient to evoke spontaneous transient depolarizations (lower trace).
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drug application (up to 10 min, Figure 4E) and was irrevers-
ible. In 2/6 cells, this depolarization was sufficient to trigger
transient depolarizations (figure 4E, lower panel).
Effect of other KCNQ channel inhibitors on
SMC currents
The KCNQ inhibitor linopirdine (30 μM) produced effects
similar to those of XE991 (Figure 5A) by reducing the
outward current at +40 mV (n = 5, P < 0.05). Chromanol
293B, an open channel inhibitor that inhibits IKs in cardiac
myocytes (Busch et al., 1996; Suessbrich et al., 1996) is spe-
cific for KCNQ1 channels (Bleich et al., 1997). Chromanol
(30 μM) significantly decreased bladder SMC currents (n = 7,
P < 0.05), as shown in the example and summary bar chart in
Figures 5B & D. In current clamp, chromanol induced a mean
depolarization of −6.4 ± 0.9 mV (P < 0.05, n = 5).
KCNQ channel activators on SMC outward
current and r.m.p.
The KCNQ activator flupirtine (20 μM) increased current
amplitude across the voltage range (Figure 6A). Summary
data is presented in the current–voltage plot in Figure 6B (n =
6, P < 0.05). Flupirtine was also observed to reduce inward
currents (Figure 6C) at the beginning of the current step, but
enhanced the outward current (at 0 mV). The effect on
inward current was examined using Cs+-filled pipettes, to
eliminate K+ currents, and stepping to 0 mV, where the
inward current was maximal. Figure 6C demonstrates the
reduction (but not abolition) of inward Ca2+ current by flu-
pirtine (20 μM), typical of six experiments. Flupirtine (20 μM)
produced a reversible hyperpolarization (mean 5 ± 1 mV, n =
7, P < 0.0001) when applied for 30–40 s to quiescent cells
(Figure 6D) and abolished activity in cells that had exhibited
spontaneous transient depolarizations (Figure 6D right
panel). MFA (20 μM) significantly increased current ampli-
tude at +40 mV (n = 11, P < 0.05; Figure 6E, F). Unlike flupir-
tine, MFA had no apparent effect on inward currents.
Molecular identification of KCNQ subtypes
expressed in bladder cells
The molecular identification of KCNQ1-5 genes in dispersed
guinea pig detrusor cells using end-point RT-PCR is shown
in Figure 7. All five KCNQ genes were expressed in guinea
pig detrusor cells. Bands of the expected sizes (KCNQ1,
434 bp; KCNQ2, 515 bp; KCNQ3, 461 bp; KCNQ4, 561 bp;
KCNQ5, 200 bp) were amplified, as observed with ethidium
bromide staining under UV light, and confirmed by
sequencing. Amplification of KCNQ2 in guinea pig bladder
resulted in two bands at 520 and 486 bp, which did not
disappear upon optimization of primer annealing tempera-
ture, in agreement with Liang et al. (2006), who demon-
strated alternative spliced forms of KCNQ2 with similar PCR
band sizes. There is a small possibility that nerve fragments
were present in the cell suspension and that neuronal or
other cellular KCNQ channels contributed to the bands;
however, this would be minimal, and the results are more
likely to represent KCNQ transcripts in the concentrated
SMC cell suspension.
KCNQ protein subtypes expressed in
bladder tissue
Immunohistochemical labelling of guinea pig bladder tissues
with antibodies to the five KCNQ subtypes confirmed the
expression of all five family members (Figure 8). The micro-
Figure 5
Effect of linopirdine and chromanol on SMC outward current. (A) Currents were evoked by stepping to +40 mV and were reduced by linopirdine
(Lino; 30 μM). (B) Outward currents were reduced by chromanol 293B (Chr; 30 μM). (C, D) Summary bar charts of the significant reduction of
SMC outward current by linopirdine (n = 5) and chromanol 293B (n = 7). *P < 0.05, significantly different from control.
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graphs demonstrate the presence of KCNQ channels in SMC
and IC, based on morphology and location from previous
published work (McCloskey and Gurney, 2002). Successful
double-labelling experiments with IC markers and KCNQ
antibodies were not feasible due to differences in the fixatives
required, but the images suggest that KCNQ1-5 are present in
both SMC and IC, which are present on the edge of, and in
the spaces between, smooth muscle bundles. KCNQ4 appears
to be predominantly expressed in the SMC, as has been
shown in vascular smooth muscle (Joshi et al., 2009). Signifi-
cant fluorescence was not present in negative control tissues,
where the primary antibody had been omitted (Figure 8F), or
where no antibodies were present to control for tissue auto-
fluorescence (Figure 8G). Control antigens were not available
for the KCNQ4 and KCNQ5 antibodies, but pre-absorption
with the antigen peptides used to generate the KCNQ1-3
antibodies also prevented staining. Positive controls were not
carried out in the present study; a parallel study by some of
Figure 6
Effect of KCNQ activators on SMC currents and resting membrane potential. (A) Example of a family of outward currents in SMC enhanced by
flupirtine (20 μM). (B) Summary of six similar experiments in which flupirtine significantly reduced the outward current at potentials between −50
and +10 mV. (C) The current evoked by stepping to 0 mV had both inward and outward components. Flupirtine reduced the inward component
at the beginning of the trace and increased the outward current over the remainder of the sweep. Right panel shows an inward Ca2+ current (at
0 mV), which was recorded using Cs+-filled electrodes in order to eliminate outward K+ currents. Flupirtine reduced the inward current amplitude.
(D) Example of a current-clamp recording where flupirtine (20 μM) caused a reversible membrane hyperpolarization in quiescent cells (left panel).
Cells which exhibited spontaneous electrical activity in the absence of drugs (right panel) ceased firing on hyperpolarization induced by flupirtine.
(E) Meclofenamic acid (MFA, 20 μM) increased amplitude of currents at +40 mV. (F) Summary bar chart showing significant enhancement of
current amplitude by MFA in 11 cells. *P < 0.05, significantly different from control.
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the authors on pulmonary artery (Joshi et al., 2009) showed
staining with a panel of KCNQ antibodies.
Discussion
The present study has provided molecular, cellular and tissue
evidence that KCNQ channels are functionally expressed in
guinea pig bladder. Patch-clamp experiments demonstrated
that a component of outward current in bladder SMC was
carried by KCNQ channels and that the r.m.p. was partly
mediated by KCNQ currents. RT-PCR demonstrated gene
expression of KCNQ1, 2, 3, 4 and 5 in SMC, and the corre-
sponding proteins were immunolabelled in detrusor tissues.
Effect of KCNQ inhibitors
KCNQ currents from bladder SMC exhibited typical proper-
ties, including activation positive to −60 mV, voltage depend-
ence, outward rectification, lack of inactivation and inhibition
by XE991, linopirdine and chromanol 293B. XE991 and its less
potent analogue linopirdine are open-channel blockers that
directly interact with KCNQ channel protein rather than
acting via G-protein or Ca2+-mediated messenger pathways
(Costa and Brown, 1997; Lamas et al., 1997). XE991 and lino-
pirdine are effective inhibitors of KCNQ/M currents, although
they are not subtype specific (Aiken et al., 1995; Lamas et al.,
1997; Wang et al., 1998). In bladder SMC, XE991 was more
potent against outward current than linopirdine, consistent
with the findings of others; XE991 inhibits KCNQ/M currents
with an IC50 of 1 μM (Wang et al., 1998) compared with
linopirdine, IC50 3.4–7.4 μM (Costa and Brown, 1997; Lamas
et al., 1997). The findings with chromanol 293B indicate that
KCNQ1 is also functionally active.
Effect of KCNQ activators
Flupirtine, and its more potent analogue, retigabine, increase
KCNQ/M-like currents and reduce excitability in neurons
Figure 7
Identification of KCNQ genes in guinea pig bladder cells. RT-PCR analysis of KCNQ1-5 gene family members in RNA extracted from dispersed
guinea pig detrusor cells. Guinea pig heart and brain tissues were used as positive controls. ‘+RT’ and ‘−RT’ represent the inclusion or omission
of reverse transcriptase respectively in the reverse transcription of mRNA to cDNA process. Bands corresponding to KCNQ1-5, as indicated by the
base pair table, were detected in guinea pig detrusor cells.
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(Tatulian et al., 2001; Martire et al., 2004; Peretz et al., 2005;
Wladyka and Kunze, 2006), and act on all KCNQ subtypes
except KCNQ1. MFA augments KCNQ2/3 channel activity by
shifting the voltage activation curve leftward and slowing the
deactivation kinetics, leading to membrane hyperpolariza-
tion (without affecting KCNQ1, Peretz et al., 2005). Flupirtine
and MFA enhanced outward currents in bladder SMC, con-
firming the presence of some, or all of the KCNQ 2–5 subu-
nits. The loss of effect of flupirtine at 20 mV and above is
consistent with the voltage-dependent effect of its related
analogue, retigabine, on neuronal KCNQ currents (Tatulian
et al., 2001).
KCNQ and the r.m.p.
The functional significance of KCNQ channels in guinea pig
bladder was demonstrated in current-clamp studies. The
experimental conditions where KATP channels and repolariz-
ing Ca2+-activated K+ currents were minimized, resulted in
spontaneous transient depolarizations with prolonged dura-
tions compared with action potentials. The inhibitors of
KCNQ channels (XE991 and chromanol) reduced the SMC
r.m.p and induced transient depolarizations. Consistent with
this, flupirtine induced a hyperpolarization and simultaneous
cessation of any firing. These findings suggest that in bladder
SMC, KCNQ channels regulate excitability by acting as a
brake on the repetitive firing of electrical activity.
KCNQ subtypes
Five gene members of the KCNQ family of ion channel pro-
teins have been identified, each encoding a different KCNQ
α-subunit (1–5). Considerable diversity in the expression of
KCNQ has been noted between tissues, with channels
expressed as heteromultimers (e.g. KCNQ2/KCNQ3) or
homomultimers with accessory subunits, such as the KCNE
or minimal K+ channel proteins (minK). Variation in the
sensitivity of KCNQ1-5 subunits to TEA is a useful tool for
elucidating the composition of KCNQ subunits in a given
cell (Wang et al., 1998; Hadley et al., 2000; Shah et al.,
2002). Hadley et al. (2000) demonstrated in transfected
CHO cells that the TEA sensitivity of KCNQ2 was high (IC50
0.3 mM), whereas KCNQ3 (IC50 > 30 mM) had a low sensi-
tivity, and intermediate sensitivities were found in KCNQ1
and KCNQ4 (IC50 5 mM and 3 mM respectively). KCNQ5
channels expressed in human brain had an IC50 value of
71 mM for TEA (Schroeder et al., 2000). In the present
study, the reduction of the TEA-resistant (30 mM) current in
bladder SMC by KCNQ blockers could be explained by an
effect on KCNQ3 or KCNQ5 channel subunits, as this con-
centration blocks KCNQ 1, 2 and 4 but not 3 and 5 (Hadley
et al., 2000). Taken together with our findings from the use
of KCNQ activators and inhibitors, our results suggest that
KCNQ1, 2, 3, 4 and 5 subunits may all be functionally
expressed in SMC from the guinea pig bladder, consistent
with the PCR and immunohistochemistry data. While we
cannot be absolutely certain that residual BK currents were
not present and therefore accounting for some of the TEA
effect, the experimental conditions were set to minimize
BK activity. This could be further explored in the future
using bladder cells and tissue from BK knockout mice. To
understand the relative contributions of the different subu-
nits, it would be helpful to know which KCNQ subunits
predominate in the SMC and which KCNE β subunits are
present to modulate their activity.
Figure 8
Detection of KCNQ gene expression by immunohistochemistry. (A–E) Whole-mount preparations of guinea pig detrusor were incubated with
antibodies to KCNQ1-5 subtypes. Immunoreactivity was detected in both smooth muscle bundles (SM) and in IC adjacent to and between the
smooth muscle bundles for the five KCNQ subtypes tested. Inset micrographs in (A–C) show minimal immunofluorescence in pre-absorption
controls for KCNQ1-3; the scale bars indicate 50 μm. (F) Micrograph of secondary antibody only control slide, showing minimal immunofluo-
rescence. (G) Micrograph of negative control (no antibodies) demonstrating absence of autofluorescence.
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Functional significance of KCNQ channels
in bladder
KCNQ channels are important in setting vascular tone; Yeung
et al. (2007) demonstrated relaxation of pre-contracted
murine aorta with flupirtine and MFA. In contrast, KCNQ
inhibitors constricted rat mesenteric (Mackie et al., 2008) and
rat or mouse intrapulmonary arteries (Joshi et al., 2006). Here,
the putative functional role of KCNQ channels in bladder was
demonstrated in bladder strips, where myogenic spontaneous
contractions were affected by KCNQ drugs, indicating that
KCNQ channels are active under these conditions. These
findings are consistent with the current-clamp studies of iso-
lated cells, in which KCNQ inhibitors reduced the membrane
potential and often elicited transient depolarizations, whereas
KCNQ activators induced hyperpolarization and simultane-
ous cessation of any spontaneous transient depolarizations.
We interpret the reduction in contractility induced by flupir-
tine with a degree of caution, however, as this could be partly
explained by its effect on L-type Ca2+ currents.
The effects of KCNQ channel inhibitors and activators on
bladder strip contractility are reasonably explained by a direct
action on SMC and not arising from depolarization of intra-
mural nerves leading to neurotransmitter release, as experi-
ments were performed in the presence of tetrodotoxin.
Interestingly, the compounds tested did affect contraction
amplitude and AUC analysis but had no overall significant
effect on frequency. Moreover, KCNQ channel inhibitors did
not significantly enhance baseline tone, typical of other
phasic smooth muscle tissues, such as uterus (McCallum
et al., 2009) and colon (Jepps et al., 2009). Ca2+ experiments
demonstrated that at the single cell level and within smooth
muscle bundles, XE991 enhanced the frequency of Ca2+-
oscillations consistent with the depolarization found in
current clamp experiments. Therefore, in normal bladder,
KCNQ channels seem to provide a fine-tuning control
mechanism over smooth muscle excitability, where inhibi-
tion of KCNQ channels can augment spontaneous contrac-
tions but is not sufficient to cause sustained contraction,
which would be undesirable during bladder filling. The
arrangement of smooth muscle in the bladder, comprising
interlocking bundles of SMC rather than a sheet arrange-
ment, as is found in the vasculature or the gut, prevents
spread of excitation across the wall and subsequent coordi-
nated contractions.
We previously reported KCNQ currents in detrusor IC and
found that they contributed to the r.m.p. (Anderson et al.,
2009). Although the functional roles of detrusor IC are not
yet fully understood, if they do act to modulate smooth
muscle activity, KCNQ channels would provide one ionic
mechanism of controlling their excitability. Streng et al.
(2004) provided evidence for the functional role of KCNQ
channels in the bladder in in vivo experiments on rats, where
intravesical administration of the KCNQ channel opener,
retigabine, decreased baseline bladder pressures in rat detru-
sor, increased micturition volume and decreased capsaicin-
induced detrusor overactivity. Recent studies of KCNQ
inhibitors and activators on rat bladder demonstrate effects
on contractility (Rode et al., 2010; Svalø et al., 2011). Our
study supports these findings and provides the first direct
electrophysiological evidence for the existence of KCNQ
channels in bladder SMC. It seems feasible that the develop-
ment of bladder-specific KCNQ openers could provide treat-
ment options for the overactive bladder. Moreover, gene
mutations of KCNQ subunits may well underlie bladder dis-
orders, as with some cardiovascular, nervous and auditory
pathologies.
Commercially available compounds were used here, and
we interpret the results within the normal understanding of
pharmacological specificity. These compounds are widely
used in research into cardiovascular or neuronal KCNQ chan-
nels and are established as reliable inhibitors or activators of
KCNQ channels (see Miceli et al., 2008; Brown and Passmore,
2009). We could not be certain that the KCNQ inhibitors and
activators would not affect other ion channels in bladder
SMC and therefore designed our experimental conditions to
eliminate other K+ currents where possible. The use of a panel
of KCNQ channel inhibitors and activators strengthens the
evidence that the effects observed were due to KCNQ channel
modulation and are less likely to be non-selective actions on
other voltage-dependent currents.
The current findings advance our knowledge of the diver-
sity of K+ channel expression in bladder smooth muscle. The
roles of BK, SK, delayed rectifier and KATP channels in bladder
electrical activity are well established, yet there are more K+
channels present, including novel TASK (Beckett et al., 2008)
and TREK channels (Baker et al., 2008), in addition to the
KCNQ channels. Clearly, bladder SMC contain a complement
of K+ channels that can be finely tuned to work together in
response to the physiological requirements of the organ
during filling and micturition. Modulation of KCNQ by mus-
carinic neurotransmitters in the bladder presents an intrigu-
ing area of future work; this mechanism is well established for
the neuronal KCNQ M current, where muscarinic stimulation
inhibits KCNQ channel activity.
In conclusion, we have presented here the first electro-
physiological evidence for KCNQ currents in bladder SMC
and their role in control of the r.m.p. Evidence for gene and
cellular expression of five members of the KCNQ family in
the guinea pig bladder detrusor is also presented. The activity
of KCNQ channel inhibitors and activators on bladder strips
suggest that KCNQ currents have a novel role in the regula-
tion of bladder contractility.
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